2022
DOI: 10.1001/jamaophthalmol.2021.6376
|View full text |Cite
|
Sign up to set email alerts
|

Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease

Abstract: Accessed January 4, 2022. https://researchinformation.bris.ac.uk/en/publications/nice-dsutechnical-support-document-18-methods-forpopulation-adj 25. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…Teprotumumab is a fully human monoclonal antibody targeting the IGF-IR. It was found to be useful in improving the proptosis, diplopia, and quality of life of TED patients [50,52 ▪▪ ,53,61,62,63 ▪▪ ]. Tocilizumab, which blocks interleukin 6 (IL-6), also demonstrated efficacy in improving the extraocular motility in 83.33%, and diplopia in 53.85% of TED patients [53,54].…”
Section: Thyroid Eye Diseasementioning
confidence: 99%
“…Teprotumumab is a fully human monoclonal antibody targeting the IGF-IR. It was found to be useful in improving the proptosis, diplopia, and quality of life of TED patients [50,52 ▪▪ ,53,61,62,63 ▪▪ ]. Tocilizumab, which blocks interleukin 6 (IL-6), also demonstrated efficacy in improving the extraocular motility in 83.33%, and diplopia in 53.85% of TED patients [53,54].…”
Section: Thyroid Eye Diseasementioning
confidence: 99%